Literature DB >> 28710095

Acute coronary syndrome in new-onset rheumatoid arthritis: a population-based nationwide cohort study of time trends in risks and excess risks.

Marie Holmqvist1, Lotta Ljung1,2, Johan Askling1.   

Abstract

BACKGROUND: Acute coronary syndrome (ACS) and other cardiovascular diseases are the main drivers of the increased morbidity and preterm mortality in rheumatoid arthritis (RA). ACS in RA has been linked to inflammation and RA severity. During recent years and with new therapeutic options and treat-to-target strategies, increasing efforts have been made to reach RA remission as soon as possible after diagnosis, and the average level of RA disease activity has declined. Whether this has resulted in declining excess risks for RA comorbidities remains unclear.
METHODS: We performed a nationwide population-based cohort study of patients with new-onset RA from 1997 to 2014, and matched general population comparators. In the Swedish healthcare system, all residents have equal access to healthcare services. Healthcare is monitored using high-quality population-based registers that can be linked together. 15 744 patients with new-onset RA, identified from the Swedish Rheumatology Quality Register, and 70 899 general population comparator subjects were included.
RESULTS: Seven hundred and seventy two patients with RA developed an ACS during 103 835 person-years of follow-up (crude incidence, 7.4 per 1000), corresponding to an overall HR versus the general population of 1.41 (95% CI 1.29 to 1.54). Whereas the ACS incidence declined over calendar time in both the RA and the general population cohort, the excess and the relative risks of ACS remained the same.
CONCLUSIONS: Despite improved disease control in new-onset RA, the elevated risk of ACS in RA remains a concern. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Rheumatoid Arthritis; Sweden; cardiovascular; cohort; risk

Mesh:

Year:  2017        PMID: 28710095     DOI: 10.1136/annrheumdis-2016-211066

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  16 in total

Review 1.  Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis.

Authors:  Anne Grete Semb; Eirik Ikdahl; Grunde Wibetoe; Cynthia Crowson; Silvia Rollefstad
Journal:  Nat Rev Rheumatol       Date:  2020-06-03       Impact factor: 20.543

2.  Assessment of hemostatic disturbances in women with established rheumatoid arthritis.

Authors:  Aleksandra Vranic; Iva Pruner; Mirjana Veselinovic; Nida Soutari; Anica Petkovic; Vladimir Jakovljevic; Aleksandra Antovic
Journal:  Clin Rheumatol       Date:  2019-06-17       Impact factor: 2.980

3.  [Clinical and immunological characteristics of myositis complicated with thromboembolism].

Authors:  F Y Zhu; X Y Xing; X F Tang; Y M Li; M Shao; X W Zhang; Y H Li; X L Sun; J He
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-12-18

4.  Multimorbidity Burden in Rheumatoid Arthritis: A Population-based Cohort Study.

Authors:  Tina M Gunderson; Elena Myasoedova; John M Davis; Cynthia S Crowson
Journal:  J Rheumatol       Date:  2021-02-15       Impact factor: 5.346

5.  Improved Incidence of Cardiovascular Disease in Patients With Incident Rheumatoid Arthritis in the 2000s: A Population-based Cohort Study.

Authors:  Elena Myasoedova; John M Davis; Veronique L Roger; Sara J Achenbach; Cynthia S Crowson
Journal:  J Rheumatol       Date:  2021-02-15       Impact factor: 5.346

6.  Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries.

Authors:  Benedicte Delcoigne; Lotta Ljung; Sella A Provan; Bente Glintborg; Merete Lund Hetland; Kathrine Lederballe Grøn; Ritva Peltomaa; Heikki Relas; Carl Turesson; Bjorn Gudbjornsson; Brigitte Michelsen; Johan Askling
Journal:  Ann Rheum Dis       Date:  2022-03-22       Impact factor: 27.973

7.  Effects of Treatment with Adalimumab on Blood Lipid Levels and Atherosclerosis in Patients with Rheumatoid Arthritis.

Authors:  Ulf Bergström; Stefan Jovinge; Jerker Persson; Lennart T H Jacobsson; Carl Turesson
Journal:  Curr Ther Res Clin Exp       Date:  2018-07-23

8.  Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis in a geographically distant National Register-based cohort: an external validation.

Authors:  Lotta Ljung; Peter Ueda; Katherine P Liao; Jeffrey D Greenberg; Carol J Etzel; Daniel H Solomon; Johan Askling
Journal:  RMD Open       Date:  2018-12-16

Review 9.  Testing the Effects of Disease-Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial.

Authors:  Jon T Giles; Pamela M Rist; Katherine P Liao; Ahmed Tawakol; Zahi A Fayad; Venkatesh Mani; Nina P Paynter; Paul M Ridker; Robert J Glynn; Fengxin Lu; Rachel Broderick; Meredith Murray; Kathleen M M Vanni; Daniel H Solomon; Joan M Bathon
Journal:  ACR Open Rheumatol       Date:  2021-05-01

10.  Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit.

Authors:  Anne Grete Semb; Silvia Rollefstad; Eirik Ikdahl; Grunde Wibetoe; Joseph Sexton; Cindy Crowson; Piet van Riel; George Kitas; Ian Graham; Solbritt Rantapää-Dahlqvist; George Athanasios Karpouzas; Elena Myasoedova; Miguel A Gonzalez-Gay; Petros P Sfikakis; Maria G Tektonidou; Argyro Lazarini; Dimitrios Vassilopoulos; Bindee Kuriya; Carol Hitchon; Maria Simona Stoenoiu; Patrick Durez; Virginia Pascual-Ramos; Dionicio Angel Galarza-Delgado; Pompilio Faggiano; Durga Prasanna Misra; Andrew A Borg; Rong Mu; Erkin M Mirrakhimov; Diane Gheta; Karen Douglas; Vikas Agarwal; Svetlana Myasoedova; Lev Krougly; Tatiana Valentinovna Popkova; Alena Tuchyňová; Michal Tomcik; Michal Vrablik; Jiri Lastuvka; Pavel Horak; Helena Kaspar Medkova; Anne M Kerola
Journal:  RMD Open       Date:  2021-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.